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Aims To assess whether the use of the femoral or radial approach for percutaneous coronary intervention (PCI) interacted
with the efficacy and safety of cangrelor, an intravenous P2Y12 inhibitor, in CHAMPION PHOENIX.
Methods
and results
A total of 11 145 patients were randomly assigned in a double-dummy, double-blind manner either to a cangrelor bolus
and 2-h infusion or to clopidogrel at the time of PCI. The primary endpoint, a composite of death, myocardial infarction,
ischaemia-driven revascularization, or stent thrombosis, and the primary safety endpoint, Global Use of Strategies to
Open Occluded Coronary Arteries (GUSTO) defined severe bleeding, were evaluated at 48 h. Of the patients under-
going PCI and receiving study drug treatment, a total of 8064 (74%) and 2855 (26%) patients underwent femoral or
radial PCI, respectively. Among the femoral cohort, the primary endpoint rate was 4.8% with cangrelor vs. 6.0%
with clopidogrel (odds ratio, OR [95% confidence interval, CI] ¼ 0.79 [0.65–0.96]); among the radial cohort, the pri-
mary endpoint was 4.4% with cangrelor vs. 5.7% with clopidogrel (OR [95% CI] ¼ 0.76 [0.54–1.06]), P-interaction 0.83.
The rate of GUSTO severe bleeding in the femoral cohort was 0.2% with cangrelor vs. 0.1% with clopidogrel (OR [95%
CI] ¼ 1.73 [0.51–5.93]). Among the radial cohort, the rate of GUSTO severe bleeding was 0.1% with cangrelor vs. 0.1%
with clopidogrel (OR [95% CI] ¼ 1.02 [0.14–7.28]), P-interaction 0.65. The evaluation of safety endpoints with the
more sensitive ACUITY-defined bleeding found major bleeding in the femoral cohort to be 5.2% with cangrelor vs.
3.1% with clopidogrel (OR [95% CI] ¼ 1.69 [1.35–2.12]); among the radial cohort the rate of ACUITY major bleeding
was 1.5% with cangrelor vs. 0.7% with clopidogrel (OR [95% CI] ¼ 2.17 [1.02–4.62], P-interaction 0.54).
Conclusion In CHAMPION PHOENIX, cangrelor reduced ischaemic events with no significant increase in GUSTO-defined severe
bleeding. The absolute rates of bleeding, regardless of the definition, tended to be lower when PCI was performed via
the radial artery.
Clinical trial
registration
http://www.clinicaltrials.gov identifier: NCT01156571.
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Introduction
The association between bleeding and increased morbidity and
mortality after percutaneous coronary intervention (PCI) has
prompted the implementation of bleeding reduction strategies at
the time of PCI.1,2 According to clinical trial data, compared with
femoral access, the radial artery approach for PCI has been demon-
strated to have similar efficacy with the benefit of reduced major
bleeding and access site complications.3 – 6 Owing to a favourable
safety profile, several guidelines endorse the radial artery as the pre-
ferred PCI access site.7,8
Cangrelor is an intravenous P2Y12 receptor antagonist with an
immediate (within 2 min) onset of action and a half-life of 3–6 min,
allowing platelet function to return to baseline within 60 min of infu-
sion cessation. In the Cangrelor vs. Standard Therapy to Achieve Op-
timal Management of Platelet Inhibition (CHAMPION) PHOENIX
trial, the intravenous P2Y12 receptor antagonist, cangrelor, reduced
the rate of ischaemic events at 48 h in patients undergoing percutan-
eous revascularization without a significant increase in severe bleed-
ing or transfusions.9 In this pre-specified secondary analysis, we
explore the efficacy and safety of cangrelor according to access site
(femoral vs. radial) in the CHAMPION PHOENIX trial.
Methods
Patient population
CHAMPION PHOENIX was a double-blind, double-dummy, placebo-
controlled trial of cangrelor in patients undergoing PCI. Both the design
and primary findings have been published previously.9,10 Briefly, 11 145
patients undergoing either elective or urgent PCI and receiving
guideline-recommended therapy were randomized after angiography
to receive a bolus (30 mg/kg) and infusion (4 mg/kg/min for a minimum
of 2 h or the duration of the procedure whichever was longer) of can-
grelor or a 600 or 300 mg loading dose of clopidogrel. The timing
(before or after PCI) and dose of clopidogrel were at the discretion
of the site investigator. The access approach for PCI was determined
by the site investigator and did not require institutional review board
(IRB) approval. At the end of the infusion, patients then received either
600 mg of clopidogrel (cangrelor group) or matching placebo (clopido-
grel group; Figure 1).
Endpoints
The primary efficacy endpoint was a composite of death (by any cause),
myocardial infarction (MI), ischaemia-driven revascularization (IDR), or
stent thrombosis in the first 48 h following randomization. Criteria for
MI within 48 h post-PCI were defined as an elevation in creatine kinase-
myocardial band (CK-MB) greater than three times the upper limit of nor-
mal or by a combination of CK-MB elevation in addition to ischaemic
symptoms, angiographic evidence, and/or ECG changes. The key second-
ary endpoint was the incidence of stent thrombosis at 48 h, which was de-
fined according to the Academic Research Consortium criteria or as
intraprocedural stent thrombosis.11 All events of death, MI, IDR, and stent
thrombosis were adjudicated. The primary safety endpoint was severe
non-coronary artery bypass grafting (CABG) bleeding according to the
Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO)
criteria. Thrombolysis In Myocardial Infarction (TIMI) and Acute Cath-
eterization and Urgent Intervention Triage strategY (ACUITY) bleeding
definitions were also evaluated. Bleeding endpoints, based on pre-
specified criteria, were derived from investigator-reported data using a
computer algorithm. Bleeding endpoints were not adjudicated.
Statistical analysis
This was a pre-specified analysis outlined in the CHAMPION PHOENIX
study protocol, which was approved by local ethics committees. Inde-
pendent verification of these analyses by Harvard Clinical Research In-
stitute did not require specific IRB approval. Efficacy analyses were
performed from the modified intention-to-treat (mITT) population,
defined as subjects undergoing PCI and receiving study drug. Bleeding
analyses were performed from the safety population, defined as subjects
receiving study drug. Baseline characteristics were summarized by
vascular access (femoral vs. radial) and treatment (cangrelor vs.
Figure 1 Study design. SA, stable angina; NSTE-ACS, non-ST segment elevation acute coronary syndrome; STEMI, ST segment elevation
myocardial infarction; PCI, percutaneous coronary intervention.
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clopidogrel); and were compared using analysis of variance for continu-
ous variables and the x2 test for categorical variables. Treatment com-
parisons within access site (cangrelor vs. clopidogrel) were not adjusted
for baseline characteristics, were based on the x2 test, and are pre-
sented as odds ratios with 95% confidence intervals (CIs). The number
needed to treat (NNT) was derived within the femoral and radial sub-
groups as the inverse of the difference between the cangrelor and clo-
pidogrel event rates. The interaction between treatment and PCI access
site was tested using the Breslow–Day method. Time-to-event curves
for the primary efficacy endpoint at 48 h were constructed using the
Kaplan–Meier method and compared using the log-rank test.
Multivariable logistic regression modelling was performed using pro-
pensity scores to assess the effect of PCI access site (femoral or radial),
using femoral approach as the reference, with study treatment in the
model and the propensity score based on the following potential vari-
ables: diagnosis at presentation, region (US/non-US), smoking status,
hyperlipidaemia, previous MI, prior PCI, prior CABG, peripheral artery
disease, planned clopidogrel loading dose (300 or 600 mg), and anticoagu-
lant (bivalirudin or heparin). Statistical analyses were conducted using the
SAS software, version 9.3 (SAS Institute, Cary, North Carolina, USA).
Results
Patients
Out of 11 145 patients randomized in CHAMPION PHOENIX, 10
942 patients comprised the mITT population who received study
treatment and underwent PCI. Of these patients, 8064 (74%) under-
went PCI via the femoral artery and 2855 (26%) via the radial ap-
proach. Three patients in the radial cohort did not complete the
48-h post-PCI follow-up and were excluded from the efficacy end-
point analyses; 23 patients underwent brachial PCI and were not
included in this analysis.
Cangrelor vs. clopidogrel
Baseline characteristics according to access site (femoral vs. radial)
and randomized treatment (cangrelor vs. clopidogrel) are depicted
in Table 1. In the femoral cohort, subjects randomized to cangrelor
had higher rates of peripheral artery disease (8.2 vs. 6.7%, P ¼ 0.01).
In the radial cohort, subjects randomized to cangrelor had a lower
median weight (84 vs. 85 kg, P ¼ 0.008).
Radial vs. femoral
Baseline characteristics according to access site only (femoral vs.
radial) are depicted in the Supplementary material online, Table S1.
Compared with the femoral cohort, subjects in the radial cohort
had higher rates of diabetes mellitus (27.3 vs. 29.7%, P ¼ 0.01)
and prior PCI (23.1 vs. 25.8%, P ¼ 0.004), but lower rates of cur-
rent smoking (29.1 vs. 27.1%, P ¼ 0.04), prior MI (21.9 vs. 17.7%,
P, 0.0001), and prior CABG (11.6 vs. 5.0%, P, 0.0001) (Supple-
mentary material online, Table S1).
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Table 1 Baseline characteristics
Femoral Radial
Cangrelor Clopidogrel P-value Cangrelor Clopidogrel P-value
Characteristic
Demographic
n 4053 4011 1410 1445
Age, years
Median 64 64 0.51 64.5 64 0.11
Interquartile range 56, 72 56, 72 57, 72 56, 71
Female sex, n (%) 1144 (28.2) 1107 (27.6) 0.53 413 (29.3) 382 (26.4) 0.09
Weight, kg
Median 84 84 0.86 84 85 0.008
Interquartile range 73, 96 73, 96 73, 95 75, 96
Medical history, n (%)
Diabetes mellitus 1106/4048 (27.3) 1094/4005 (27.3) 1.00 409/1407 (29.1) 438/1444 (30.3) 0.46
Current smoker 1142/3950 (28.9) 1148/3918 (29.3) 0.70 357/1380 (25.9) 398/1408 (28.3) 0.15
Hypertension 3239/4040 (80.2) 3156/3998 (78.9) 0.17 1127/1410 (79.9) 1164/1442 (80.7) 0.59
Hyperlipidaemia 2434/3507 (69.4) 2366/3447 (68.6) 0.49 923/1336 (69.1) 963/1376 (70.0) 0.61
Prior stroke or TIA 210/4039 (5.2) 180/3996 (4.5) 0.15 61/1407 (4.3) 61/1442 (4.2) 0.89
Prior myocardial infarction 844/4030 (20.9) 914/3982 (23.0) 0.03 245/1402 (17.5) 258/1435 (18.0) 0.73
Prior PTCA or PCI 913/4045 (22.6) 947/4003 (23.7) 0.25 353/1408 (25.1) 383/1444 (26.5) 0.38
CABG 495/4048 (12.2) 436/4006 (10.9) 0.06 81/1409 (5.7) 63/1444 (4.4) 0.09
Heart failure 412/4044 (10.2) 443/4002 (11.1) 0.20 137/1407 (9.7) 140/1440 (9.7) 0.99
Peripheral artery disease 328/4015 (8.2) 268/3978 (6.7) 0.01 119/1384 (8.6) 112/1427 (7.8) 0.47
TIA, transient ischaemic attack; PTCA, percutaneous transluminal coronary angioplasty; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft.
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Procedure characteristics
Cangrelor vs. clopidogrel
Procedure characteristics according to access site (femoral vs.
radial) and randomized treatment (cangrelor vs. clopidogrel) are
depicted in Table 2. In the femoral cohort, subjects randomized to
cangrelor had lower rates of glycoprotein IIb/IIIa inhibitor use (2.7
vs. 4.3%, P ¼ 0.0001).
Femoral vs. radial
Procedure characteristics according to access site only (femoral vs.
radial) are depicted in the Supplementary material online, Table S2.
Patients in the radial cohort had lower rates of aspirin (94.9 vs.
92.6%, P, 0.0001) and low molecular weight heparin (14.4 vs.
11.4%, P, 0.0001) use, but had higher rates of unfractionated hep-
arin (75.2 vs. 86.3%, P, 0.0001) use at the time of PCI compared
with patients in the femoral cohort. The clopidogrel 600 mg loading
dose was used less often in the femoral (67.1%) cohort compared
with the radial (95.1%) cohort, P, 0.0001. Percutaneous coronary
intervention duration (17 min femoral vs. 18 min radial, P ¼ 0.34)
and success rate (98.2% femoral and 98.3% radial, P ¼ 0.68) were
similar in both groups. Of the femoral cohort, 53.5% of patients re-
ceived a drug eluting stent, compared with 61.8% of patients in the
radial cohort, P, 0.001.
Outcomes
Cangrelor vs. clopidogrel
In the femoral cohort, the rate of the primary efficacy endpoint of
death, MI, IDR, or stent thrombosis at 48 h was 4.8% with cangrelor
vs. 6.0% with clopidogrel (odds ratio [OR] 95% CI ¼ 0.79 [0.65–
0.96]), NNT 84; in the radial cohort, the primary efficacy endpoint
rate was 4.4% with cangrelor vs. 5.7% with clopidogrel (OR [95%
CI] ¼ 0.76 [0.54–1.06]), P-interaction ¼ 0.83; NNT 74. Figure 2A
and B depicts the Kaplan–Meier estimates for the time-to-event
for the primary endpoint in both the femoral and radial cohorts.
Among the femoral cohorts, the key secondary endpoint of stent
thrombosis at 48 h was 0.8% with cangrelor vs. 1.5% with clopido-
grel (OR [95% CI] ¼ 0.52 [0.34–0.80]); in the radial cohort, the rate
of stent thrombosis at 48 h was 0.9% with cangrelor vs. 0.8% with
clopidogrel (OR [95% CI] ¼ 1.11 [0.51–2.45]), P-interaction 0.09.
The effects of cangrelor on the primary and secondary endpoints
in the overall study population and according to access site are
shown in Figure 3A.
In both access cohorts, there were no significant differences in
the rates of GUSTO severe bleeding, TIMI major bleeding, or blood
transfusions in patients treated with cangrelor compared with clopi-
dogrel. In the femoral cohort, the rate of ACUITY major bleeding
was 5.2% with cangrelor vs. 3.1% with clopidogrel (OR [95%
CI] ¼ 1.69 [1.35–2.12), P, 0.0001; in the radial cohort, the rate
of ACUITY major bleeding was 1.5% with cangrelor vs. 0.7% with
clopidogrel (OR [95% CI] ¼ 2.17 [1.02–4.62]), P ¼ 0.04 and
P-interaction 0.54. The effects of cangrelor on bleeding according
to access site and categorized by the various bleeding criteria are
listed in Table 3. The effects of cangrelor on bleeding in the overall
study population and according to access site are shown in Figure 3B.
Femoral vs. radial
Among patients undergoing PCI via the femoral artery, the rate of
the primary efficacy endpoint at 48 h was 5.4 vs. 5.1% in the radial
group (unadjusted OR 95% CI ¼ 0.95 [0.78–1.15]), P ¼ 0.58. After
multivariable analysis, compared with patients undergoing PCI via
the femoral artery, there was no difference in the adjusted rate of
primary efficacy endpoint in the radial access cohort (OR [95%
CI] ¼ 1.03 [0.81–1.29]), P ¼ 0.83. Efficacy endpoints (unadjusted
and adjusted) according to access site are displayed in Supplemen-
tary material online, Table S3.
In the femoral cohort, the rate of GUSTO severe/moderate
bleeding was 0.5% compared with 0.2% in the radial cohort
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Table 2 Procedure characteristics
Femoral Radial
Cangrelor Clopidogrel P-value Cangrelor Clopidogrel P-value
Indication, n (%) 0.95 0.06
Stable angina 2290/4053 (56.5) 2258/4011 (56.3) 888/1410 (63.0) 905/1445 (62.6)
NSTE-ACS 1099/4053 (27.1) 1085/4011 (27.1) 365/1410 (25.9) 341/1445 (23.6)
STEMI 664/4053 (16.4) 668/4011 (16.7) 157/1410 (11.1) 199/1445 (13.8)
Antithrombotic, n (%)
Aspirin 3851/4050 (95.1) 3796/4007 (94.7) 0.47 1304/1410 (92.5) 1338/1444 (92.7) 0.86
Clopidogrel, 300 mg loading dose (planned) 1322/4053 (32.6) 1332/4011 (33.2) 0.57 79/1410 (5.6) 62/1445 (4.3) 0.11
Clopidogrel, 600 mg loading dose (planned) 2731/4053 (67.4) 2679/4011 (66.8) 0.57 1331/1410 (94.4) 1383/1445 (95.7) 0.11
Low molecular weight heparin 580/4053 (14.3) 579/4011 (14.4) 0.87 150/1410 (10.6) 174/1443 (12.1) 0.23
Unfractionated heparin 3045/4053 (75.1) 3020/4010 (75.3) 0.85 1220/1410 (86.5) 1243/1445 (86.0) 0.70
Fondaparinux 117/4053 (2.9) 92/4011 (2.3) 0.09 39/1409 (2.8) 43/1445 (3.0) 0.74
Bivalirudin 944/4053 (23.3) 940/4009 (23.4) 0.87 307/1410 (21.8) 326/1445 (22.6) 0.61
Glycoprotein IIb/IIIa inhibitor 111/4053 (2.7) 173/4011 (4.3) 0.0001 41/1410 (2.9) 54/1445 (3.7) 0.22
NSTE-ACS, non-ST-elevation acute coronary syndrome; STE ACS, ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention.
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(unadjusted OR [95% CI] ¼ 0.46 [0.21–1.02]; P ¼ 0.05). The rate
of TIMI major/minor bleeding in the femoral cohort was 0.2%
compared with 0.1% in the radial cohort (unadjusted OR [95%
CI] ¼ 0.63 [0.21–1.85]; P ¼ 0.39). Lastly, the rate of ACUITY
major/minor bleeding was 14.5% in the femoral cohort and 9.2%
in the radial group (unadjusted OR [95% CI] ¼ 0.60 [0.52–0.68];
P, 0.0001). After multivariable analysis, compared with PCI
via the femoral artery, using the radial approach was associated
with a decreased odds of GUSTO severe/moderate (OR [95%
CI] ¼ 0.35 [0.12–1.01]; P ¼ 0.05), TIMI major/minor bleeding
(OR [95% CI] ¼ 0.34 [0.07–1.54]; P ¼ 0.16), and ACUITY major/
minor bleeding (OR [95% CI] ¼ 0.70 [0.59–0.83]; P, 0.0001
(Table 4).
Discussion
Intravenous adenosine diphosphate (ADP) receptor blockade with
cangrelor, when compared with clopidogrel, reduced the primary
composite outcome of death, MI, IDR, or stent thrombosis at
48 h after randomization regardless of PCI access site. Among the
femoral access subjects, cangrelor compared with clopidogrel re-
duced the odds of the primary composite outcome by 21%; within
the radial cohort, there was a consistent 24% reduction in the odds
of the primary composite outcome. Although the interaction tests
for access site did not reach statistical significance, when the primary
composite endpoint was evaluated according to access site, cangre-
lor demonstrated a reduction in odds of ischaemic events among
Figure 2 (A) Kaplan–Meier curves for the primary efficacy endpoint in the subgroup undergoing femoral access (cangrelor vs. clopidogrel).
(B) Kaplan–Meier curves for the primary efficacy endpoint in the subgroup undergoing radial access (cangrelor vs. clopidogrel). HR, hazard ratio;
CI, confidence interval.
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patients undergoing femoral PCI. In patients undergoing PCI via the
radial artery, cangrelor demonstrated a non-significant trend to-
wards fewer ischaemic events, likely due to lack of statistical power
because of a smaller sample size. In the femoral cohort, cangrelor’s
benefit with respect to ischaemic events was driven by a reduction
in MI and stent thrombosis, consistent with the overall CHAMPION
PHOENIX results. The radial cohort, however, only experienced a
reduction in MI. The lack of benefit regarding stent thrombosis in
the radial cohort is conceivably due to a low event frequency within
this particular subgroup: 95 total (1.2%) in the femoral vs. 25 total
(0.9%) in the radial.
In both the femoral and radial groups, cangrelor compared with
clopidogrel was not associated with a significant increase in the
pre-specified GUSTO-defined severe bleeding, the primary safety
Figure 3 (A) Efficacy of cangrelor vs. clopidogrel in the femoral and radial subgroups. MI, myocardial infarction; IDR, ischaemia-driven revascu-
larization; ST, stent thrombosis; OR, odds ratio; CI, confidence interval. (B) Bleeding with cangrelor vs. clopidogrel in the femoral and radial sub-
groups. GUSTO, Global Use of Strategies to Open Occluded Arteries; TIMI, Thrombolysis In Myocardial Infarction; ACUITY, Acute
Catheterization and Urgent Intervention Triage strategY; OR, odds ratio; CI, confidence interval.
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Table 3 Safety endpoints at 48 h after randomization
Endpoint Femoral Radial P-interaction
Cangrelor Clopidogrel OR (95% CI) P-value Cangrelor Clopidogrel OR (95% CI) P-value
GUSTO bleeding
Severe or life threatening 7/4052 (0.2) 4/4012 (0.1) 1.73 (0.51–5.93) 0.37 2/1411 (0.1) 2/1444 (0.1) 1.02 (0.14–7.28) 0.98 0.65
Moderate 20/4052 (0.5) 12/4012 (0.3) 1.65 (0.81–3.39) 0.16 2/1411 (0.1) 1/1444 (0.1) 2.05 (0.19–22.61) 0.55 0.87
Severe/moderate 27/4052 (0.7) 16/4012 (0.4) 1.68 (0.90–3.11) 0.10 4/1411 (0.3) 3/1444 (0.2) 1.37 (0.31–6.11) 0.68 0.80
TIMI bleeding
Major 3/4052 (0.1) 3/4012 (0.1) 0.99 (0.20–4.91) 0.99 2/1411 (0.1) 2/ 1444 (0.1) 1.02 (0.14–7.28) 0.98 0.98
Minor 9/4052 (0.2) 3/4012 (0.1) 2.97 (0.80–11.00) 0.09 0/1411 (0.0) 0/1444 (0.0)
Major/minor 12/4052 (0.3) 6/4012 (0.1) 1.98 (0.74–5.29) 0.16 2/1411 (0.1) 2/1444 (0.1) 1.02 (0.14–7.28) 0.98 0.55
ACUITY bleeding
Major 209/4052 (5.2) 125/4012 (3.1) 1.69 (1.35–2.12) ,0.0001 21/1411 (1.5) 10/1444 (0.7) 2.17 (1.02–4.62) 0.04 0.54
Minor 510/4052 (12.6) 369/4012 (9.2) 1.42 (1.23–1.64) ,0.0001 139/1411 (9.9) 94/1444 (6.5) 1.57 (1.19–2.06) 0.001 0.53
Major/minor 690/4052 (17.0) 483/4012 (12.0) 1.50 (1.32–1.70) ,0.0001 158/1411 (11.2) 104/1444 (7.2) 1.62 (1.25–2.11) 0.0002 0.59
Blood transfusion 22/4052 (0.5) 14/4012 (0.3) 1.56 (0.80–3.05) 0.19 3/1411 (0.2) 2/1444 (0.1) 1.54 (0.26–9.21) 0.63 0.99
GUSTO, Global Use of Strategies to Open Occluded Arteries; Thrombolysis In Myocardial Infarction; ACUITY, Acute Catheterization and Urgent Intervention Triage strategY; OR, odds ratio; CI, confidence interval.
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endpoint, or in blood transfusions; though more sensitive definitions
such as ACUITY-defined bleeding did show increased rates of
bleeding with cangrelor in both the femoral and radial cohorts. It
is important to note that the absolute rates of GUSTO severe/mod-
erate bleeding and blood transfusions were approximately two to
three times higher with the femoral approach compared with the
radial, in both the cangrelor and clopidogrel arms of the study.
These findings are consistent with prior studies. The analysis of all
femoral vs. radial randomized PCI clinical trials has found radial ac-
cess, when compared with femoral, to be associated with a 42% re-
duction in non-CABG bleeding.5 Contemporary studies have
demonstrated that up to 70% of bleeding events occurring in the
PCI setting can be attributed to complications arising at the site of
vascular access.12 The present study suggests that in a large contem-
porary international trial, the radial approach for PCI has the poten-
tial to play a key role in reducing periprocedural bleeding in a wide
variety of PCI patients.
It is postulated that a reduction in access site bleeding may in turn
lead to fewer subsequent adverse events.13 For example, the afore-
mentioned 42% reduction in major non-CABG bleeding associated
with the radial approach for PCI was paralleled with an aggregate re-
duction of major adverse cardiac events (death, MI, or stroke) of
14%, P ¼ 0.005.5 After multivariable analysis the present study finds
the odds of periprocedural bleeding 30–66% lower, depending on
bleeding definition, when PCI was performed via the radial artery
compared with the femoral approach. However, the favourable
bleeding profile associated with the radial artery approach to PCI
in CHAMPION PHOENIX did not translate into a reduction in
the primary efficacy endpoint at 48 h.
There are certain limitations to this analysis. First, similar to the
overall CHAMPION PHOENIX trial, there is the potential for the
benefit of cangrelor to be attenuated in the setting of more pro-
longed pretreatment with clopidogrel or with the use or ticagrelor
or prasugrel. Secondly, bleeding endpoints were not adjudicated.
Thirdly, the treatment by radial vs. femoral access was not rando-
mized and even with the adjusted analyses, there may be residual
confounding. Lastly, CHAMPION PHOENIX was not powered to
test the interaction between treatment and PCI access site; there-
fore, all interaction terms should be interpreted with caution.
In CHAMPION PHOENIX, intravenous ADP-receptor inhibition
with cangrelor reduced ischaemic events with no significant increase
in severe bleeding or blood transfusions regardless of PCI access
site. Compared with the femoral approach, rates of bleeding com-
plications appeared to be lower with radial access for PCI in both
randomized arms of the study.
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Table 4 Safety endpoints at 48 h: radial vs. femoral
Endpoint Femoral Radial OR (95% CI) unadjusted P-value OR (95% CI) adjusted P-value
GUSTO bleeding
Severe or life threatening 11/8064 (0.1) 4/2855 (0.1) 1.03 (0.33, 3.23) 0.96
Moderate 32/8064 (0.4) 3/2855 (0.1) 0.26 (0.08, 0.86) 0.02
Severe/moderate 43/8064 (0.5) 7/2855 (0.2) 0.46 (0.21, 1.02) 0.05 0.35 (0.12–1.01) 0.05
TIMI bleeding
Major 6/8064 (0.1) 4/2855 (0.1) 1.89 (0.53, 6.67) 0.32
Minor 12/8064 (0.1) 0/2855 (0.0) – 0.04
Major/minor 18/8064 (0.2) 4/2855 (0.1) 0.63 (0.21, 1.85) 0.39 0.34 (0.07–1.54) 0.16
ACUITY bleeding
Major 334/8064 (4.1) 31/2855 (1.1) 0.25 (0.18, 0.37) ,0.0001
Minor 879/8064 (10.9) 233/2855 (8.2) 0.72 (0.63, 0.85) ,0.0001
Major/minor 1173/8064 (14.5) 262/2855 (9.2) 0.60 (0.52, 0.68) ,0.0001 0.70 (0.59–0.83) ,0.0001
All non-CABG bleeding 1173/8064 (14.5) 262/2855 (9.2) 0.60 (0.52, 0.68) ,0.0001
GUSTO, Global Use of Strategies to Open Occluded Arteries; Thrombolysis In Myocardial Infarction; ACUITY, Acute Catheterization and Urgent Intervention Triage strategY;
CABG, coronary artery bypass graft; OR, odds ratio; CI, confidence interval.
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